NYSE · AZN
Healthcare · Drug Manufacturers - General
$162.70
Down-$2.07 (-1.26%)
Updated Sep 8, 2026, 6:16 AM
SID Score
7.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AZN closed at $162.70 after 20 trading sessions, up 0.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $162.82 | $163.78 | $161.13 | $162.70 | 3.07M |
| Sep 3, 2026 | $165.64 | $165.74 | $162.24 | $164.77 | 2.43M |
| Sep 2, 2026 | $162.54 | $164.69 | $160.87 | $161.63 | 3.3M |
| Sep 1, 2026 | $163.66 | $164.24 | $161.385 | $162.47 | 2.6M |
| Aug 31, 2026 | $162.70 | $163.75 | $161.95 | $162.13 | 3.07M |
| Aug 28, 2026 | $163.52 | $163.54 | $161.18 | $162.70 | 2.88M |
| Aug 27, 2026 | $165.27 | $165.58 | $163.98 | $164.52 | 2.5M |
| Aug 26, 2026 | $167.46 | $167.89 | $165.17 | $166.27 | 2.68M |
| Aug 25, 2026 | $167.08 | $170.18 | $166.78 | $169.66 | 3.45M |
| Aug 24, 2026 | $164.57 | $167.08 | $163.97 | $166.71 | 2.78M |
| Aug 21, 2026 | $164.04 | $167.25 | $163.96 | $165.98 | 3.18M |
| Aug 20, 2026 | $163.40 | $165.57 | $161.475 | $164.49 | 5.09M |
| Aug 19, 2026 | $162.13 | $165.91 | $162.00 | $164.95 | 3.82M |
| Aug 18, 2026 | $159.12 | $160.64 | $158.98 | $160.10 | 3M |
| Aug 17, 2026 | $156.30 | $157.26 | $155.78 | $156.89 | 3.36M |
| Aug 14, 2026 | $155.50 | $156.46 | $154.53 | $156.45 | 3.7M |
| Aug 13, 2026 | $157.85 | $158.44 | $156.97 | $157.24 | 3.6M |
| Aug 12, 2026 | $157.68 | $159.0226 | $157.12 | $158.50 | 4.14M |
| Aug 11, 2026 | $162.06 | $162.26 | $158.61 | $158.75 | 2.75M |
| Aug 10, 2026 | $160.59 | $162.72 | $160.25 | $161.91 | 3.75M |
The latest Smart Investors Daily articles mentioning AZN.
AZN research
Company profile and research snapshot.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
Generated Sep 7, 2026, 9:05 PM
AstraZeneca shares declined 1.26% despite positive regulatory news, suggesting the market may have already priced in recent drug approvals or investors are taking profits. The company secured notable FDA wins for its breast cancer treatment ETCAMAH, but the modest sell-off indicates broader market dynamics or sector headwinds are currently outweighing the good news.
Bottom line: AstraZeneca's regulatory victories with ETCAMAH represent genuine clinical and commercial progress, yet today's selloff reflects the market's cautious stance or profit-taking behavior. Investors should view this dip as a potential entry point given the drug's strong approval trajectory, though they should monitor competitive dynamics and real-world adoption rates as the critical factors determining long-term value creation.
Yahoo · Sep 7, 2026
Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination...
Yahoo · Sep 7, 2026
Evinova's Unified Trial Solution will integrate with Lothar Medical's devices, providing sites and patients connected data.
Yahoo · Sep 5, 2026
With UK gilt yields responding to shifting Bank of England expectations, investors are rethinking where dependable long term growth could come from. Healthcare companies using artificial intelligence to improve diagnosis and treatment sit at the crossroads of technology and essential services, which can matter when borrowing costs and inflation concerns move in and out of focus. This article highlights three UK listed AI healthcare stocks from our screener to put on your radar. The stocks...
Yahoo · Sep 4, 2026
WILMINGTON, Del., September 04, 2026--AstraZeneca’s ETCAMAH® (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized te
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC shares currently trade at $162.70, reflecting a modest 1.01% gain over the past month but a notable 12.5% decline over the trailing three-month period, per SID market data. On a one-year basis, the stock has delivered a substantial $98.15 return, underscoring significant long-term appreciation. Technically, AZN trades below its 50-day moving average of $169.10, suggesting near-term weakness, while holding above its 200-day moving average of $160.35, which indicates the broader uptrend remains intact. The 14-day RSI stands at 60.5, placing the stock in neutral territory without overbought or oversold signals. AZN's beta of 0.168, according to Massive/Polygon data, reflects exceptionally low volatility relative to the broader market, consistent with its defensive healthcare sector positioning. Average daily trading volume registers at approximately 5.47 million shares, supporting adequate liquidity for institutional participants.
AstraZeneca carries a market capitalization of approximately $279.9 billion, positioning it among the largest global pharmaceutical companies, per SID market data. The stock trades at a price-to-earnings ratio of 33.06, which represents a premium to the broader healthcare sector, according to SEC filings and market data. The PEG ratio stands at 4.53, indicating that the current earnings multiple is elevated relative to the company's projected growth rate, suggesting limited value on a growth-adjusted basis. AZN's price-to-book ratio of 6.24 further reflects the market's premium valuation of the company's asset base, likely driven by its robust oncology and biopharmaceutical pipeline. The dividend yield registers at 1.56%, providing a modest income component for shareholders. Collectively, these metrics indicate AstraZeneca commands a growth-oriented premium, with investors pricing in sustained pipeline-driven revenue expansion and margin improvement over the medium term.
AstraZeneca's composite smart money score stands at 58 out of 100, generating a neutral signal according to SID market data. The institutional component scores a perfect 25 out of 25, reflecting strong and sustained institutional ownership and accumulation patterns per 13F institutional filings. Insider activity scores 12.5 out of 25, with SEC Form 4 filings showing three insider transactions over the past 90 days — all of which were purchases with zero insider sales recorded. This unanimously bullish insider buying pattern suggests management confidence in the company's forward prospects. Dark pool activity scores a relatively low 8.9 out of 25, indicating limited off-exchange block trading activity in recent periods. Congressional trading activity registers at 12 out of 25, reflecting moderate legislative interest. The divergence between the strong institutional score and the modest dark pool reading creates a mixed overall profile, though the absence of any insider selling represents a constructive signal for shareholders monitoring executive sentiment.
AstraZeneca has demonstrated a pattern of significant earnings outperformance in its most recently reported quarters. Per company earnings reports, the company posted earnings of $2.63 per share against an analyst estimate of $1.52, delivering a positive surprise of $1.11. The following reported quarter showed similarly strong results, with actual earnings of $2.58 versus the consensus estimate of $1.53, representing a $1.05 beat. These consecutive substantial beats suggest analysts may be systematically underestimating AstraZeneca's earnings power. Looking ahead, analyst estimates project earnings of $1.75 per share for the upcoming quarter with results expected on April 28, while the subsequent quarter carries an estimate of $1.44 with a July 28 reporting date. Given the magnitude of recent positive surprises exceeding 68% above estimates, the forward consensus figures may present upside potential if the company's operational momentum and pipeline milestones continue at their current trajectory.
Wall Street coverage on AstraZeneca reveals a divided analyst community, per SID consensus data. In the most recent rating activity, Berenberg Bank reiterated a Buy rating on July 13, 2026, reinforcing its constructive stance on the company's outlook. Jefferies has also maintained a Buy rating on two separate occasions, issuing reiterations on both June 9 and June 26, according to Wall Street analyst reports. Conversely, Deutsche Bank stands as a notable bear, reiterating a Sell rating twice — on June 11 and June 26 — representing the sole negative voice among recent coverage updates. This creates a clear bifurcation, with two out of three covering firms maintaining bullish positions while one firm holds a bearish view. The absence of any Hold ratings among recent actions indicates strong conviction on both sides of the debate, suggesting analysts view AstraZeneca's pipeline catalysts and valuation as decisive factors warranting directional positioning rather than a neutral stance.
The latest Smart Investors Daily articles mentioning AZN.
